New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why certain ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

There's a long way to go when it comes to sex and gender equity in medicine, but engineers at The University of New Mexico hope to close the gap with ...

Obesity doesn’t just increase your risk of metabolic diseases it may also raise the risk of developing and progressing ...

A Carlow mother diagnosed with stage 4 ovarian cancer is raising vital funds for her treatment in order to give her more time ...

Clinical application: Treatment in a mouse model with milciclib in combination with mirvetuximab significantly reduced tumor ...